Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01018875 | Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease | PHASE2 | COMPLETED | 242 | — | — | Dec 1, 2009 | Feb 1, 2011 | Jun 6, 2018 | 21 | Russia, Ukraine |
| Arm | Type | Description |
|---|---|---|
| Arm 1, Dose 1, ABT-288 | EXPERIMENTAL | Low Dose |
| Arm 2, Dose 2, ABT-288 | EXPERIMENTAL | High dose |
| donepezil | ACTIVE_COMPARATOR | - |
| sugar pill | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ABT-288 | DRUG | Subjects will take 4 capsules once daily for 12 weeks. |
| donepezil | DRUG | Subjects will take 4 capsules once daily for 12 weeks. |
| placebo | DRUG | Subjects will take 4 capsules once daily for 12 weeks. |
Inclusion Criteria: 1. Have voluntarily signed an informed consent. 2. Subject meets diagnostic criteria criteria for probable AD (Alzheimer's Disease). 3. Female subjects must be postmenopausal for at least 2 years or surgically sterile. 4. Male subjects must be surgically sterile, sexually inactiv...